Thursday 16 October, 2025
Objectives: Bile acids (BA) represent a diverse class of cholesterol metabolism end products undergoing enterohepatic circulation (EHC), with a primary function…
Read morePoster: Drug/Disease Modelling - Endocrine
Population Pharmacokinetics of Survodutide in Subjects with Overweight or Obesity with and without Type 2 Diabetes Mellitus Based on Phase I and Phase II Data
Thursday 16 October, 2025
Objectives: Agonists of incretin receptors are increasingly developed as novel treatment options in a range of metabolic diseases. Survodutide is a…
Read moreA population pharmacokinetic (PK) model of metformin regarding immediate and extended release formulations under fasted and fed conditions
Thursday 16 October, 2025
Objectives: Metformin is a widely used biguanide glucose lowering agent and used as the first-line treatment for type 2 diabetes mellitus…
Read moreMathematical modeling of the oral glucose tolerance test in pre-diabetic patients: An IMI DIRECT study
Thursday 16 October, 2025
Objectives: The oral glucose tolerance test (OGTT) is well-established and commonly used for the diagnosis and study of type 2…
Read moreMathematical modeling of glucose, insulin and c-peptide during the OGTT in pre-diabetic subjects: A DIRECT study
Thursday 16 October, 2025
Objectives: Development of a mechanistic model of glucose, insulin and c-peptide levels during an oral glucose tolerance test (OGTT) in…
Read moreQuantifying the growth hormone lowering effect of BIM23B065 after a GH stimulation test
Thursday 16 October, 2025
Objectives: To establish the pharmacokinetic-pharmacodynamic relationship of a novel somatostatin-dopamine chimeric compound (BIM23B065) on a growth hormone (GH) stimulation test….
Read moreImpact of genotype assumption in a semi-mechanistic PK model of metformin
Thursday 16 October, 2025
Objectives: Develop a semi-mechanistic model of metformin PK and investigate the impact of different ways of handling missing genetic variants…
Read moreLinking 4GI Glucose Homeostasis and Hall Body Composition Models to study GLP-1R Agonist effects on glucose and body weight
Thursday 16 October, 2025
Objectives: Our previously published 4GI systems pharmacology model describes the interrelationships between glucose, glucagon-like peptide-1 (GLP-1), glucagon, glucose-dependent insulinotropic peptide…
Read moreFrom In Vitro Efficacy to Long-term HbA1c Response for GLP-1R/GlucagonR Agonism using the 4GI-HbA1c Systems Model
Thursday 16 October, 2025
Background: Type 2 diabetes mellitus (T2DM) is a complex metabolic disorder characterised by elevated blood glucose levels. Besides glucose, haemoglobin…
Read moreA novel integrated QSP model of in vivo human glucose regulation to support development of a glucagon/GLP-1 dual agonist.
Thursday 16 October, 2025
Objectives: MEDI0382 is a synthetic peptide with both glucagon-like peptide-1 (GLP-1) and glucagon receptor co-agonist activity. The combination of GLP-1…
Read more